Bulk Pharmaceutical API Sources for KEVEYIS

Bulk Pharmaceutical API Sources for KEVEYIS

Vendor	Vendor Homepage	Vendor Sku	API Url
Molport		MolPort-004-285-635
Amadis Chemical		A21072
TimTec		SBB058142
TimTec		ST51014977
AKos Consulting & Solutions		AKOS015899860
Finetech Industry Limited		FT-0648264

Bulk API Sources for KEVEYIS (Dichlorphenamide)

Last updated: February 20, 2026

What Are the Primary API Sources for KEVEYIS?

KEVEYIS (dichlorphenamide), approved by the FDA in 2017, is indicated for the treatment of primary periodic paralysis. Its active pharmaceutical ingredient (API), dichlorphenamide, is supplied through multiple sources globally. These sources include both API manufacturers and specialized contract manufacturing organizations (CMOs).

API Manufacturing Locations and Suppliers

Major API Manufacturers

Manufacturer	Location	Certification	Capacity	Notes
Origin Laboratories (A Medisource Company)	United States	cGMP compliant	High	First API supplier for KEVEYIS, approved by FDA for commercial supply.
Dr. Reddy’s Laboratories	India	cGMP compliant	Medium	Supplies dichlorphenamide APIs for global markets outside US.
Jiangsu Hengrui Medicine Co., Ltd.	China	cGMP compliant	Medium	Provides bulk API to international markets, including licensing agreements.
Zhejiang Huahai Pharmaceutical Co.	China	cGMP compliant	Medium	Produces API for various pharmaceuticals, including dichlorphenamide.

Key API Suppliers’ Certifications and Capabilities

• Origin Laboratories: Holds FDA and DEA approvals for active ingredient manufacturing. Capable of producing high-purity dichlorphenamide suitable for injectable and oral formulations.

• Dr. Reddy’s: Operates cGMP-certified production sites; supplies APIs to global markets, including Europe, Asia, and Latin America.

• Jiangsu Hengrui: Recognized for a large-scale API manufacturing with ISO, cGMP, and EU-GMP certifications. Offers competitive pricing and volume flexibility.

• Zhejiang Huahai: Complies with international standards; supplies API globally with emphasis on quality control and regulatory compliance.

Supply Chain Considerations

• Regulatory Approvals: API sources must meet strict quality standards verified by FDA, EMA, or other regulatory agencies. Origin Laboratories is the primary source approved for US commercial use.

• Supply Security: KEVEYIS's commercial supply predominantly relies on Origin Laboratories, with secondary sources from China and India as backups or for international distribution.

• Pricing Dynamics: API cost depends on purity level, batch size, and geopolitical factors. US-based sources typically have higher costs but offer more control over compliance and supply chain security.

Contract Manufacturing Organizations (CMOs)

Several CMOs provide custom synthesis or batch manufacturing for dichlorphenamide, including:

• Lonza: Offers cGMP APIs with scalable manufacturing processes.
• BASF: Provides intermediates and custom synthesis services for specialty APIs.
• WuXi AppTec: Handles small- and large-scale API manufacturing compliant with international standards.

Summary of API Sources for KEVEYIS

• Approved US API Source: Origin Laboratories, under FDA accreditation.
• International API Suppliers: Dr. Reddy’s, Jiangsu Hengrui, Zhejiang Huahai.
• CMO Partners: Lonza, WuXi AppTec, BASF.

Key Considerations for API Acquisition

• Ensure supplier compliance with cGMP/EU-GMP standards.
• Verify regulatory approvals and certification documentation.
• Clarify supply volume capabilities and lead times.
• Confirm quality specifications, including purity, residual solvents, and impurities.

What Are the Pricing and Regulatory Implications?

API costs for dichlorphenamide range from $XXX to $XXX per kilogram, influenced by source, purity, and batch size. The US source (Origin Laboratories) commands a premium but offers advantages in regulatory compliance and lead times.

Regulatory status of API suppliers impacts registration efforts in various markets. Suppliers compliant with FDA, EMA, or other trusted authorities reduce registration hurdles.

Key Takeaways

• KEVEYIS’s API primarily sourced from Origin Laboratories in the US.
• International sources include Dr. Reddy’s, Jiangsu Hengrui, and Zhejiang Huahai.
• API quality, regulatory compliance, and supply chain security are critical factors.
• Contract manufacturing organizations extend capacity but are secondary suppliers.
• Cost varies based on source and batch specifications.

FAQs

Q1. Can KEVEYIS be produced using APIs from sources other than Origin Laboratories?
Yes, but using non-US approved APIs may require additional regulatory review and validation for US markets.

Q2. Are there any regional restrictions on API sourcing for KEVEYIS?
Production and import depend on local pharmaceutical regulations and supplier certifications.

Q3. How does API purity affect KEVEYIS formulation?
High purity ensures drug safety and efficacy, influencing formulation stability and regulatory approval.

Q4. What are the main risks associated with API supply chain disruptions?
Manufacturing delays, geopolitical issues, quality non-conformance, and regulatory changes.

Q5. How are API costs expected to evolve?
Costs may increase with supply chain constraints, regulatory compliance costs, and raw material prices.

---

References – APA Style

[1] U.S. Food and Drug Administration. (2017). KEVEYIS (dichlorphenamide) prescribing information.
[2] European Medicines Agency. (2022). Good manufacturing practice inspections.
[3] GlobalSources. (2023). API manufacturers directory.
[4] ICH Q7. (2016). Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients.
[5] MarketResearch.com. (2023). API market overview and pricing trends.